-
Buffets, baristas, but no briefings: journalists frozen out of Iran talks
-
McIlroy's Masterpiece remains the buzz at Augusta
-
Sinner brushes past Zverev to reach Monte Carlo final
-
Arsenal suffer major blow in Premier League title charge
-
UK puts Chagos handover deal in 'deep freeze' after Trump criticism
-
In Europe first, Netherlands to allow Teslas to self-drive
-
Sabrina Carpenter transforms Coachella into her own 'Sabrinawood'
-
Iran, Lebanon bore brunt of missiles and drones launched during war
-
Iran envoys meet Pakistani PM ahead of US talks
-
UK to shelve Chagos handover after Trump criticism
-
Somalia president congratulates World Cup-bound referee Omar Artan
-
Vance in Islamabad for Iran talks overshadowed by mutual mistrust
-
After Artemis II, NASA looks to SpaceX, Blue Origin for Moon landings
-
Benin leans into painful past to attract tourists
-
Britain storm into Billie Jean King Cup finals with Australia thumping
-
Russia and Ukraine set to begin Easter truce
-
Hawks clinch NBA playoff berth with win over Cavs
-
Trump administration reveals plans for massive Washington arch
-
Carney poised to win Canada majority but affordability pressure looms
-
Artemis II lunar mission draws flood of conspiracy theories
-
Extra time at Augusta helps McIlroy make Masters magic
-
Panic buttons, undercover cops: How Peru bus drivers try to stay safe
-
Iran, US to hold peace talks overshadowed by mutual mistrust
-
Artemis II astronauts return to Earth, capping historic Moon mission
-
Small US farm copes with fuel hikes from Mideast war
-
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX)
-
McIlroy seizes 36-hole record six-shot Masters lead with epic finish
-
Iranian delegation in Pakistan for talks with US, Vance en route
-
Rory McIlroy seizes Masters record six-stroke lead after 36 holes
-
Djibouti leader claims sixth straight term
-
Trump vows to boost Hungary economy if Orban wins vote
-
Mythos AI alarm bells: Fair warning or marketing hype?
-
De Zerbi 'not surprised' by backlash from Spurs fans over Greenwood
-
Marseille boost hopes of Champions League return, Monaco suffer heavy defeat
-
Frustrated Scheffler finds water hazards at Masters
-
Swing and miss: Ichiro statue reveal goes awry as bat snaps
-
China's Li flushes toilet trouble at Masters
-
Stocks up, oil down over week on guarded optimism for Iran
-
Real Madrid title hopes dented by Girona draw
-
Malen hits hat-trick as Roma rebound against declining Pisa
-
Playoff loss to McIlroy not motivating 'nearly man' Rose
-
Lebanon says Israel talks set for Tuesday in US
-
West Ham sink Wolves to climb out of relegation zone as Spurs slip into bottom three
-
OpenAI CEO's California home hit by Molotov cocktail, man arrested
-
Holders Italy and Ukraine make strong starts in BJK Cup as USA trail
-
Top takeaways from the Artemis II mission
-
McIlroy seizes command at the turn at Masters
-
Hatton jumps into Masters hunt with stunning 66
-
African charity sues Prince Harry for defamation
-
Fury happy to be the 'hunter' on return to ring
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2025, after the stock market closes on Thursday, November 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1739504&tp_key=71dd648c0e. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 20, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13756671.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
W.Nelson--AT